Login
Companies $ZTS
$84.55 +$0.16 (0.19%) After hours
Zoetis Inc. logo

Zoetis Inc.

zoetis.com

What Do They Do?

Sells animal-health medicines, vaccines and diagnostics for pets and livestock to veterinarians, pet owners and livestock producers.

How Do They Make Money?

Companion-animal products are the largest business; Zoetis sells products directly or through distributors, retailers and e-commerce outlets, with sales occurring when goods ship and payment terms generally ranging from 30 to 90 days.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Livestock
Sold outright

29%
FY2022: 35%
Companion Animal
Sold outright

70%
FY2022: 64%
Contract Manufacturing and Human Health Diagnostics
1.2%
FY2022: 1.1%

Who Are Their Customers?

Zoetis sells companion-animal products to veterinarians and veterinary distributors, who typically resell to veterinarians; livestock products go to veterinarians and producers, directly or through distributors and retailers.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: 15% from one customer

Do Revenues Turn Into Profits?

Yes. It kept 28 cents of every revenue dollar as net income in FY2025 and turned 24 cents into free cash flow.

Operating income, FY2025
37% of revenue
▲ +6% vs FY2024 ($3.3B, 36%)
Net income, FY2025
28% of revenue
▲ +8% vs FY2024 ($2.5B, 27%)
Free cash flow, FY2025
24% of revenue
▼ −1% vs FY2024 ($2.3B, 25%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −1%
vs $2.4B in Q3 FY2025
Net income
▼ −18%
vs $721M in Q3 FY2025
Companion Animal share of revenue vs 68.1% in Q3 FY2025
  • Aug 6, 2026 Zoetis appoints a CFO as its current CFO transitions to adviser James Saccaro is appointed CFO and COO effective August 17, 2026; Wetteny Joseph moves from CFO to an advisory role.

Growing. Revenue grew 22% in 4 years, from $7.8B in FY2021 to $9.5B in FY2025, about 5% a year.

Medicated feed additives The earlier report included medicated feed additives among its product categories; the latest says Zoetis divested that portfolio and related assets, and no longer includes the category.

Revenue over time
Livestock Companion Animal Contract Manufacturing and Human Health Diagnostics
$10B$5B$0

Who Do They Compete With?

Competes with Boehringer Ingelheim, Merck &, Elanco Animal Health, and IDEXX Laboratories

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support